Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Stocks · News reference
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Cathie Wood's Ark Invest added to positions in Nvidia, Broadcom, and Intellia Therapeutics on Friday as these stocks declined. Nvidia exceeded earnings expectations with 106% revenue growth and raised guidance to 70% for fiscal 2028, now trading at 14x forward earnings. Broadcom is on track for accelerating growth with an upcoming earnings report. Intellia, a gene-editing biotech, has declined over 50% from recent highs but remains well-funded with analyst support.
Cathie Wood's ARK sold 40,392 Shopify shares after a 25% August rally. Here's what ARKK and ARKW are betting on next.
Palantir stock slumps as Google’s new AI push raises concerns over its government business and lofty valuation.
Ark Invest sold $15.6 million of Tempus AI and $3.4 million of AMD on Tuesday, Sept. 1, 2026.
Cathie Wood sold Palantir following its earnings beat, shifting capital into Block and Circle amid a broader Bitcoin and Ethereum rally.